New drug cocktail aims to fight tough bile duct cancer
NCT ID NCT06548412
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding an experimental drug called CTX-009 to standard chemotherapy (gemcitabine and cisplatin) plus immunotherapy (durvalumab) can safely treat advanced biliary tract cancer that cannot be removed by surgery. About 50 adults will receive the combination intravenously. The main goal is to check for side effects, but researchers will also watch for signs that the tumors shrink or stop growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTX-009 (an experimental drug) combined with gemcitabine, cisplatin, and durvalumab
What this could lead to
If successful, this combination could improve tumor control and survival for people with advanced biliary tract cancer, a disease with limited treatment options.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply broadly. Adding more drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact